Login / Signup

Safety and response after peptide receptor radionuclide therapy with 177 Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial.

Atsushi KudoUkihide TateishiRyo-Ichi YoshimuraJunichi TsuchiyaKota YokoyamaShoko TakanoNoritoshi KobayashiDaisuke UtsunomiyaMasaharu HataYasushi IchikawaMinoru TanabeMakoto HosonoSeigo Kinuya
Published in: Journal of hepato-biliary-pancreatic sciences (2021)
Lu-DOTATATE demonstrated remarkable tumor shrinkage and tolerability in Japanese patients with advanced NETs.
Keyphrases
  • neuroendocrine tumors
  • open label
  • clinical trial
  • phase iii
  • study protocol
  • phase ii
  • randomized controlled trial
  • pet ct
  • stem cells
  • double blind
  • binding protein
  • mesenchymal stem cells
  • replacement therapy